Dr. Jonathan Katz, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 339
Licensed in California since 1995, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Tulane University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A54410 (first issued 1995; current) -
Anatomic Pathology & Clinical Pathology Physician
CA license A54410 (first issued 1995; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- California PAcific Medical Center- Van Ness Campus San Francisco, CA
- Sutter Amador Hospital Jackson, CA
- California PAcific Medical Center - Mission Bernal San Francisco, CA
- Sutter Santa Rosa Regional Hospital Santa Rosa, CA
Medical groups
- Sutter Bay Medical Foundation (3,829 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 339
- Services billed
- 785
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 236 | 138 |
| New patient office or other outpatient visit, 60-74 minutes | 61 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 58 | 51 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 39 |
| Evaluation for physical therapy, typically 20 minutes | 27 | 21 |
| Evaluation for occupational therapy, typically 30 minutes | 24 | 17 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 23 | 20 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 21 | 20 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Radicava Ors (edaravone) | 150 |
| Riluzole | 127 |
| Gabapentin Other prescribers in San Francisco, CA | 121 |
| Prednisone Other prescribers in San Francisco, CA | 92 |
| Gammaplex (immun glob g(igg)/gly/iga 0-50) | 68 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 57 |
| Azathioprine Other prescribers in San Francisco, CA | 43 |
| Mycophenolate Mofetil Other prescribers in San Francisco, CA | 43 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 31 |
| Evrysdi (risdiplam) | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 34 payments worth $56,097 in total to this clinician.
| Janssen Research & Development, LLC | $16,200 |
|---|---|
| Grifols USA, LLC | $12,748 |
| Novavax Inc | $10,500 |
| Genzyme Corporation | $10,360 |
| Amgen Inc. | $3,513 |
| Grifols Shared Services North America, Inc. | $2,100 |
| Argenx US, Inc. | $396 |
| Pfizer Inc. | $89.30 |
| Consulting Fee | $52,598 |
|---|---|
| Travel and Lodging | $2,503 |
| Food and Beverage | $997 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC Jun 2, 2025 | Consulting Fee | $16,200 |
| Novavax Inc Jan 16, 2025 | Consulting Fee NOVAVAX COVID-19 VACCINE, ADJUVANTED · Vaccine | $10,500 |
| Genzyme Corporation May 30, 2025 | Consulting Fee | $10,360 |
| Grifols USA, LLC Nov 22, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $10,000 |
| Grifols Shared Services North America, Inc. Jul 25, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $2,100 |
| Amgen Inc. Dec 16, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,925 |
| Amgen Inc. Nov 11, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,513 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $1,352 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $744 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC | $212 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Dec 16, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,925 |
| Grifols USA, LLC Nov 22, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $10,000 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $1,352 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $744 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC | $212 |
| Amgen Inc. Nov 11, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $1,513 |
| Grifols Shared Services North America, Inc. Jul 25, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $2,100 |
| Janssen Research & Development, LLC Jun 2, 2025 | Consulting Fee | $16,200 |
| Genzyme Corporation May 30, 2025 | Consulting Fee | $10,360 |
| Argenx US, Inc. May 16, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Diego, CA | $82.60 |
| Argenx US, Inc. May 16, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Diego, CA | $58.00 |
| Argenx US, Inc. May 16, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Diego, CA | $31.06 |
| Argenx US, Inc. May 16, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to San Diego, CA | $23.44 |
| Novavax Inc Jan 16, 2025 | Consulting Fee NOVAVAX COVID-19 VACCINE, ADJUVANTED · Vaccine | $10,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $103,738 in research payments for these studies, mostly to the institutions running them.
- Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
Ptc Therapeutics, Inc. · Terminated · NCT05349721 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
AbbVie Inc. · Terminated · NCT04948645 - Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
UCB SA · Completed · NCT04225871 - A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Lon…
Biogen, Inc. - Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Argenx US, Inc. - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.